

Attachment 6

FORM PTO-1449 (Modified)		Attorney Docket No. 011823-002630	Serial No.: 08/484,537 Page # 19
LIST OF PATENTS AND PUBLICATIONS FOR APPLICANT'S INFORMATION DISCLOSURE STATEMENT (Use several sheets if necessary)		Applicant: Queen	
		Filing Date: 6/7/95	Group: 1806

Reference Designation

U.S. PATENT DOCUMENTS

Examiner Initial	Document No.	Date	Name	Class	Sub-class	Filing Date (If Appropriate)
AA						
AB						
AC						
AD						
AE						
AF						
AG						
AH						
AI						
AJ						
AK						
AL						

FOREIGN PATENT DOCUMENTS

	Document No.	Date	Country	Class	Sub-class	Translation (yes/no)
AN	EP 0456216	10/16/91	EP			
AO	WO 96/05229	2/22/96	WIPO			
AP	WO 92/11018	7/9/92	WIPO			
AQ	EP 239400	8/3/94	EP			
AR	WO 90/07861	7/26/90	WIPO			
AS	WO 91/09966	7/11/91	WIPO			
AT	WO 92/11383	7/9/92	WIPO			
AU	WO 93/06231	4/1/93	WIPO			
AV	WO 96/05229	2/22/96	WIPO			

OTHER ART (Including Author, Title, Date, Pertinent Pages, Etc.)

A1	Opposition to EP 0456216 by Medical Research Council including all documents supplied therewith
	Incomplete Citation

Julie C. Reevs, PLD

14 April 99

FORM PTO-1449 (Modified)

Attorney Docket No.  
011823-002630

Serial No.: 08/484,537

LIST OF PATENTS AND PUBLICATIONS FOR  
APPLICANT'S INFORMATION DISCLOSURE  
STATEMENT  
(Use several sheets if necessary)

Applicant: Queen

Filing Date: 6/7/95

Group: 1806

<input type="checkbox"/> A2	Opposition to EP 0456216 by <b>ICOS Corporation</b> including all documents supplied therewith
<input type="checkbox"/> A3	Opposition to EP 0456216 by <b>CIBA-GEIGY AG</b> including all documents supplied therewith
<input type="checkbox"/> A4	Opposition to EP 0456216 by <b>Celltech Therapeutics</b> including all documents supplied therewith
<input type="checkbox"/> A5	Opposition to EP 0456216 by <b>Bayer AG</b> including all documents supplied therewith
<input type="checkbox"/> A6	Opposition to EP 0456216 by <b>Chiron Corporation</b> including all documents supplied therewith
<input type="checkbox"/> A7	Opposition to EP 0456216 by <b>SmithKline Beecham plc</b> including all documents supplied therewith
<input type="checkbox"/> A8	Opposition to EP 0456216 by <b>Genentech, Inc.</b> including all documents supplied therewith
<input type="checkbox"/> A9	Opposition to EP 0456216 by <b>IDEA Pharmaceuticals Corporation</b> including all documents supplied therewith
<input type="checkbox"/> A10	Opposition to EP 0456216 by <b>Bioteest Pharma GbmH</b> including all documents supplied therewith
<input type="checkbox"/> A11	Opposition to EP 0456216 by <b>BIOTRANSPLANT, INC.</b> including all documents supplied therewith
<input type="checkbox"/> A12	Opposition to EP 0456216 by <b>Bristol-Myers Squibb Company</b> including all documents supplied therewith
<input type="checkbox"/> A13	Opposition to EP 0456216 by <b>Glaxo Group Limited</b> including all documents supplied therewith
<input type="checkbox"/> A14	Opposition to EP 0456216 by <b>Boehringer Ingelheim GmbH</b> including all documents supplied therewith
<input type="checkbox"/> A15	Opposition to EP 0456216 by <b>Merck Patent GmbH</b> including all documents supplied therewith
<input type="checkbox"/> A16	Opposition to EP 0456216 by <b>Chugai Seiyaku Kabushiki Kaisha</b> including all documents supplied therewith
<input type="checkbox"/> A17	Opposition to EP 0456216 by <b>Shering Corporation</b> including all documents supplied therewith
<input type="checkbox"/> A18	Opposition to EP 0456216 by <b>Ixsys, Inc.</b> including all documents supplied therewith
<input type="checkbox"/> A19	Patentee's Observations on the Argument of the Opponents to EP 0456216, including Letter to the EPO, Observations, Exhibit I, "List of Documents Cited in the Proceedings", 0 and copies of D-88 to D-102
<input type="checkbox"/> A20	Protest Under 37 CFR §1.291 submitted by Protein Design Labs, Inc. against Celltech's US application bound with ten attachments including Protein Design Labs Opposition to Celltech's EP 0460167

Julie (Rees, P.D)

14 Apr 1999

FORM PTO-1449 (Modified)		Attorney Docket No. 011823-002630	Serial No.: 08/484,537
LIST OF PATENTS AND PUBLICATIONS FOR APPLICANT'S INFORMATION DISCLOSURE STATEMENT (Use several sheets if necessary)		Applicant: Queen	
		Filing Date: 6/7/95	Group: 1806
<input type="checkbox"/> A21	<del>Kettleborough et al., "Humanization of a Mouse Monoclonal Antibody by CDR Grafting, the Importance of Framework Residues on Loop Formation", Protein Engineering, V. 4(7), pp. 773-783, 1991</del>		
<input type="checkbox"/> A22	<del>Chothia, et al., "Conformations of Immunoglobulin Hypervariable Regions", Nature V. 342, pp. 877-883, 12/89</del>		
<input type="checkbox"/> A23	<del>Chothia, et al., "Canonical Structures for the Hypervariable Regions of Immunoglobulins", J. Mol. Biol. V. 196, pp. 901-917, 1987</del>		
<input type="checkbox"/> A24	<del>Co, et al., "Chimeric and Humanized Antibodies with Specificity for the CD33 Antigen", PDL Labs, Journal of Immunology, V. 148, pp. 1149-1154, 2/15/92</del>		
<input type="checkbox"/> A25	<del>Caron, et al., "Biological and Immunological Features of Humanized M195 (Anti-CD33) Monoclonal Antibodies", Cancer Research, V. 52, pp. 6761-6767, 12/15/92</del>		
<input type="checkbox"/> A26	<del>Appendix I, Comparison of Humanized and Donor CAMPATH-1 Heavy Chains</del>		
EXAMINER	Julie C Reeves, DABP DATE CONSIDERED 14 April 99		

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

FORM PTO-1449 (Modified)		Attorney Docket No. 011823-002630	Serial No.: 08/484 RECEIVED			
LIST OF PATENTS AND PUBLICATIONS FOR APPLICANT'S INFORMATION DISCLOSURE STATEMENT (Use several sheets if necessary)		Applicant: Queen				
		Filing Date: 6/7/95	Group: 1806 JUL 28 1998 MATRIX CUSTOMER SERVICE CENTER			
Reference Designation		U.S. PATENT DOCUMENTS				
Examiner Initial	Document No.	Date	Name			
QR AA	5,530,101	6/25/96	Queen			
FOREIGN PATENT DOCUMENTS						
	Document No.	Date	Country	Class	Sub-class	Translation (yes/no)
AM QR	A2-0120 694	(10/84)	EP	—	—	
AN QR	WO92/11018	(07/92)	WO	—	—	
AO QR	WO93/02191	(02/93)	WO	—	—	
AP QR	A1-0368 684	(05/90)	EP	—	—	
AQ QR	WO94/11509	(05/94)	WO	—	—	
AR QR	A1-0519 596	(12/92)	EP	—	—	
AS QR	A1-0592 106	(04/94)	EP	—	—	
AT QR	A1-0125 023	(11/84)	EP	—	—	
AU QR	A2-0239 400	(09/87)	EP	—	—	
AV QR	B1-0239 400	(09/87)	EP	—	—	
AW QR	A2-0188 941	(10/87)	GB	—	—	
AX QR	WO88/09344	(12/88)	WO	—	—	
AY QR	A1 0318 554	(06/89)	EP	—	—	
AZ QR	WO89/01783	(03/89)	WO	—	—	
A1 QR	A1-0323 806	(07/89)	EP	—	—	
A2 QR	A 0328 404	(08/89)	EP	—	—	
A3 QR	WO89/09622	(10/89)	WO	—	—	
A4 QR	A2 0365 209	(04/90)	EP	—	—	
A5 QR	A2 0365 997	(05/90)	EP	—	—	
OTHER ART (Including Author, Title, Date, Pertinent Pages, Etc.)						
D1 QR	Wu and Kabat, J. Exp. Med., 132 (1970) 211-250					
D2 QR	Palm, Hoppe-Seyler's Z. Physio Chem. 354 (1973), 1651-1654 Abstract only					
D3 QR	Epp., Eur. J. Biochem. 45 (1974), 513-524					
D4 QR	Palm, Hoppe-Seyler's Z. Physio. Chem. 356 (1975), 167-191 Abstract only					

Julie Cleaves PLD

13 Ja 99

FORM PTO-1449 (Modified)		Attorney Docket No. 011823-002630	Serial No.: 08/484,537
LIST OF PATENTS AND PUBLICATIONS FOR APPLICANT'S INFORMATION DISCLOSURE STATEMENT (Use several sheets if necessary)		Applicant: Queen	
		Filing Date: 6/7/95	Group: 1806
D62	QR Kabat, Sequences of Proteins of Immunological Interest, US Dept. of Health and Human Services, 1991 Edition <i>Pages vii -&gt; xxvii</i>		
D63	QR Co, J. Immunol., 148, (1992), 1149-1154		
D64	QR Foote, J. Mol. Biol., 224, (1992), 487-499		
D65	QR Carter, Proc. Natl. Acad. Sci., USA, 89 (1992) 4285-4289		
D66	Queen Application (Protein Design Laboratories) See AN <i>See Foreign Patent Documents</i>		
D67	Waldmann Application (Wellcome Foundation) See AO " " " " "		
D68	QR Tempest, Hybridoma, 13 (1994), 183-190		
D69	QR Corti, J. Mol. Biol., 235 (1994), 53-60		
D70	QR Adair, Hum. Antibod. Hybridomas, 5, (1994), 41-47		
D71	QR Padlan, Molecular Immunol., 31 (1994), 169-217		
D72	QR Ellis, J. Immunol., 155 (1995), 925-937		
D73	QR Tempest, Int. J. Biol. Macromol., 17 (1995), 37-42		
D74	QR Ohtomo, Molecular Immunology, 32 (1995), 407-416		
D75	QR Co, Cancer Res., 56 (1996), 1118-1125		
D76	QR Rosen, Dictionary of Immunology, 12, 50, 99, 100		
D77	QR Verhoeven D1.3 slide		
D78	QR Pages 6 to 8 of USSN 07/310,252 (priority document claimed by the Opposed Patent)		
D79	QR Alignment of rat YTH 34.5, human REI and humanized HuVLCAMP VL sequences from Dr		
D80	EP 0 093 619, Decision of November 8, 1995		
D81	QR Declaration of Dr. Winter (O I)		
D82	QR Declaration of Dr. Tempest (O II)		
D83	QR Declaration of Dr. Riechmann (O VIII)		
D84	QR Declaration of Dr. Chothia (O III)		
D85	QR Declaration of Dr. Padlan (O IX)		
D86	QR Declaration of Dr. Rees (O XI)		
D87	QR Biotest Experimental Report (O X)		
D88	QR Comparison chart of light chain sequences described in Riechmann (D36)		
D89	QR Rodrigues, Int. J. Cancer: Supplement 7 (1992) 45-50		
D90	QR Sha, Cancer Biotherapy, 9 (1994), 341-349		
D91	QR Winter (Medical Research Council) See AP <i>See Foreign Patent Documents</i>		

Dulie Rees PLD

13 JZ 99

FORM PTO-1449 (Modified)

Attorney Docket No.  
011823-002630Serial No.:  
08/484,537LIST OF PATENTS AND PUBLICATIONS FOR  
APPLICANT'S INFORMATION DISCLOSURE  
STATEMENT  
(Use several sheets if necessary)

Applicant: Queen

Filing Date: 6/7/95

Group: 1806

D92	Couto, Hybridoma, 13 (1994), 215-219	See Foreign Patent Document
D93	<del>Couto (Cancer Research Fund of Contra Costa) See A2</del>	
D94	<del>Padlan Application (Merck &amp; Co., Inc./NIH) See AR</del>	See Foreign Patent Document
D95	<del>Pedersen Application (Immunogen) See AS</del>	
D96	Couto, Cancer Research, Supplement 55, (1995), 1717-1722	
D97	Nakatani, Protein Engineering, 7, (1994), 435-443	
D98	Presta, Cancer Research, 57, (1997), 4593-4599	
D99	Hieter, J. Biol. Chem., 257, (1982), 1516-1522	
D100	"Polygen Corporation" in New Products, Chemical Design Corporation, Automation, 3(11), November 1988	
D101	"Biosym Technologies" in New Products, Chemical Design Automation, 3(4), December 1988	
D102	Vicenti, New Engl. J. Med., 338 (1998), 161-165	
EXAMINER	REAGAN PLD	DATE CONSIDERED 13 Jan 99

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.